|
|
Vaccine Comparison
|
SCB-2019 |
V-01-351/V-01D Bivalence Vaccine |
VBI-2902a |
| Vaccine Information |
Vaccine Information |
Vaccine Information |
- Manufacturer: Clover Biopharmaceuticals, GSK, Dynavax
- Vaccine Ontology ID: VO_0004994
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Immunization Route: Intramuscular injection (i.m.)
|
- Manufacturer: Livzon Pharmaceutical Group Inc.
- Vaccine Ontology ID: VO_0005412
- Type: Subunit vaccine
- Status: Licensed
- Host Species for Licensed Use: Human
- Immunization Route: Intramuscular injection (i.m.)
|
- Manufacturer: VBI Vaccines Inc.
- Vaccine Ontology ID: VO_0005238
- Type: Virus Like Particle
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: SARS-CoV-2 spike glycoprotein (S protein) (NCT04773665)
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
Host Response |
Host Response |
|
Baboon Response
- Immune Response: . SCB-2019 with no adjuvant elicited minimal immune responses (three seroconversions by day 50), but SCB-2019 with fixed doses of either AS03 or CpG/Alum adjuvants induced high titres and seroconversion rates of binding and neutralising antibodies in both younger and older adults (Richmond et al., 2021)
- Side Effects: Most local adverse events were mild injection-site pain (Richmond et al., 2021)
|
Baboon Response
- Efficacy: In particular, V-01D-351 booster showed the highest pseudovirus neutralizing antibody titers against prototype SARS-CoV-2, Delta and Omicron BA.1 strains at day 14 post boosting, with GMTs 22.7, 18.3, 14.3 times higher than ICV booster, 6.2, 6.1, 3.8 times higher than V-01 booster (10 μg), and 5.2, 3.8, 3.5 times higher than V-01 booster (25 μg), respectively (Zhang et al., 2022).
|
Baboon Response
- Immune Response: Antibody binding and neutralization titers were undiminished for more than 3 months after a single immunization. A single dose of this candidate, named VBI-2902a, protected Syrian golden hamsters from challenge with SARS-CoV-2 and supports the on-going clinical evaluation of VBI-2902a as a highly potent vaccine against COVID-19. (Fluckiger et al., 2021)
|
| References |
References |
References |
Richmond et al., 2021: Peter Richmond 1, Lara Hatchuel 2, Min Dong 3, Brenda Ma 3, Branda Hu 3, Igor Smolenov 3, Ping Li 3, Peng Liang 3, Htay Htay Han 3, Joshua Liang 3, Ralf Clemens 4. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. . 2021; ; . [PubMed: 33524311].
|
Zhang et al., 2022: Zhiren Zhang 1, Qiaren He 2, Wei Zhao 1, Yong Li 1, Jiaming Yang 3, Zhenxiang Hu 3, Xi Chen 3, Hua Peng 4, Yang-Xin Fu 5, Long Chen 2, Ligong Lu 1. A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains. . ; ; . [PubMed: 35887928].
|
Fluckiger et al., 2021: Anne-Catherine Fluckiger 1, Barthelemy Ontsouka 2, Jasminka Bozic 2, Abebaw Diress 2, Tanvir Ahmed 2, Tamara Berthoud 2, Anh Tran 3, Diane Duque 3, Mingmin Liao 4, Michael McCluskie 3, Francisco Diaz-Mitoma 5, David E Anderson 5, Catalina Soare 2. An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity. . 2021; ; . [PubMed: 34304928].
NCT04773665: Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate (VBI-2902a) [https://clinicaltrials.gov/ct2/show/NCT04773665]
|
|
